Patents by Inventor Derek L. Crookes

Derek L. Crookes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Medicaments
    Patent number: 5554639
    Abstract: 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide sulphate salt (2:1) and pharmaceutically acceptable solvates thereof are disclosed. The compound is of use in the preparation of pharmaceutical compositions, particularly for intranasal formulations, for use in the treatment of conditions associated with cephalic pain, in particular migraine.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: September 10, 1996
    Assignee: Glaxo Group Limited
    Inventors: Joanne Craig, Derek L. Crookes, Stephen J. Skittrall
  • Preparation of indole derivatives
    Patent number: 5103020
    Abstract: A method for the preparation of 3-(2-aminoethyl)-N-methyl-1H-indole-5-methanesulphonamide by reaction of 4-hydrazino-N-methylbenzenemethanesulphonamide and 4-chloro-1-hydroxybutanesulphonic acid, sodium salt in the presence of an acid.
    Type: Grant
    Filed: June 20, 1991
    Date of Patent: April 7, 1992
    Assignee: Glaxo Group Limited
    Inventors: Frederick D. Albinson, John W. M. MacKinnon, Derek L. Crookes
  • Process for forming Form 2 ranitidine hydrochloride
    Patent number: 4672133
    Abstract: A novel crystal form of ranitidine (N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2- nitro-1,1-ethenediamine) hydrochloride, designated Form 2, and having favorable filtration and drying characteristics, is characterized by its infra-red spectrum and/or by its x-ray powder diffraction patterns.
    Type: Grant
    Filed: March 18, 1985
    Date of Patent: June 9, 1987
    Assignee: Glaxo Group Limited
    Inventor: Derek L. Crookes
  • Aminoalkyl furan derivative
    Patent number: 4521431
    Abstract: A novel crystal form of ranitidine (N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2- nitro-1,1-ethenediamine) hydrochloride, designated Form 2, and having favorable filtration and drying characteristics, is characterized by its infra-red spectrum and/or by its x-ray powder diffraction patterns.
    Type: Grant
    Filed: August 9, 1982
    Date of Patent: June 4, 1985
    Assignee: Glaxo Group Limited
    Inventor: Derek L. Crookes